Catalyst Pharmaceuticals, Inc. $CPRX Shares Sold by Aberdeen Group plc

Aberdeen Group plc trimmed its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 38.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 387,910 shares of the biopharmaceutical company’s stock after selling 244,531 shares during the quarter. Aberdeen Group plc owned approximately 0.32% of Catalyst Pharmaceuticals worth $9,054,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of CPRX. Deerfield Management Company L.P. boosted its holdings in Catalyst Pharmaceuticals by 72.8% in the third quarter. Deerfield Management Company L.P. now owns 4,974,767 shares of the biopharmaceutical company’s stock valued at $98,003,000 after purchasing an additional 2,095,291 shares in the last quarter. American Century Companies Inc. boosted its holdings in Catalyst Pharmaceuticals by 43.8% in the third quarter. American Century Companies Inc. now owns 2,528,186 shares of the biopharmaceutical company’s stock valued at $49,805,000 after purchasing an additional 770,198 shares in the last quarter. Fundsmith LLP increased its position in shares of Catalyst Pharmaceuticals by 24.2% during the third quarter. Fundsmith LLP now owns 3,363,807 shares of the biopharmaceutical company’s stock worth $66,267,000 after purchasing an additional 654,721 shares in the last quarter. Glenmede Investment Management LP increased its position in shares of Catalyst Pharmaceuticals by 781.8% during the third quarter. Glenmede Investment Management LP now owns 680,224 shares of the biopharmaceutical company’s stock worth $13,400,000 after purchasing an additional 603,084 shares in the last quarter. Finally, Bank of America Corp DE increased its position in shares of Catalyst Pharmaceuticals by 30.6% during the second quarter. Bank of America Corp DE now owns 2,365,675 shares of the biopharmaceutical company’s stock worth $51,335,000 after purchasing an additional 554,200 shares in the last quarter. 79.22% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on CPRX. Citigroup lifted their target price on Catalyst Pharmaceuticals from $33.00 to $35.00 and gave the stock a “buy” rating in a research report on Tuesday, March 3rd. Cantor Fitzgerald upgraded Catalyst Pharmaceuticals to a “strong-buy” rating in a research report on Friday, March 27th. Weiss Ratings reiterated a “buy (b-)” rating on shares of Catalyst Pharmaceuticals in a research report on Friday, March 27th. Zacks Research upgraded Catalyst Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, March 3rd. Finally, Truist Financial upgraded shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, March 25th. Three investment analysts have rated the stock with a Strong Buy rating and three have assigned a Buy rating to the company. According to data from MarketBeat, Catalyst Pharmaceuticals currently has an average rating of “Strong Buy” and a consensus target price of $34.00.

Catalyst Pharmaceuticals Price Performance

Shares of NASDAQ:CPRX opened at $24.99 on Wednesday. The stock has a market cap of $3.05 billion, a P/E ratio of 14.79, a P/E/G ratio of 0.72 and a beta of 0.67. The firm has a fifty day moving average price of $24.14 and a 200 day moving average price of $22.95. Catalyst Pharmaceuticals, Inc. has a 1-year low of $19.05 and a 1-year high of $26.58.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).